Constitution & Law

SC terms exorbitant drug pricing by pharma firms as 'extortion'

Edition: 23 September 2026Published: 23 Sept 2026 · Updated: 23 Sept 2026UPSCSSC

In Brief

Supreme Court declared exorbitant prices charged for medicines by pharma firms and retailers as extortion and dacoity.

The Supreme Court expressed shock over patients and their families being fleeced by pharmaceutical companies and retail medicine sellers. The apex court stated that exorbitant prices charged for drugs were nothing short of 'extortion' and 'dacoity'.

Source: Currents/Amit Anand Choudhary

#Supreme-Court#drug-pricing#pharmaceuticals#extortion#healthcare

Expert Study NotesHIGHGS2 — Polity & Governance; GS3 — Economy

GS2 — Polity & Governance; GS3 — Economy

📌 Exam Angle

Prelims may ask: "Which constitutional article empowers SC to intervene in drug pricing?" or "Define extortion under IPC in pharma context." Mains could demand: "Analyze judicial activism in healthcare regulation and its constitutional implications" OR "Discuss whether price controls violate economic freedom under Article 19(1)(g)."

⚠️ Key Concerns

Tension between free market principles (Article 19(1)(g)) and right to health (Article 21). SC's use of harsh language ('extortion/dacoity') raises questions about judicial overreach vs. legitimate activism. Regulatory gap: whether DPCO (Drugs Price Control Order) adequately protects patients or if stronger statutory measures are needed.

💡 Why It Matters

Medicine pricing directly impacts India's healthcare accessibility and public health outcomes—critical for inclusive growth. This judgment signals SC's willingness to protect vulnerable citizens' constitutional right to life through aggressive pricing interventions, reshaping pharma-government-citizen dynamics.

🔑 Must Remember

• SC termed exorbitant drug pricing as 'extortion' and 'dacoity'—equating commercial practice with criminal acts • Right to Health (Article 21) vs. Commercial Freedom (Article 19) creates judicial tension in pricing regulation • DPCO's effectiveness and need for stricter regulatory oversight are key takeaways

📝 Key Terms

Drug Pricing Control Order (DPCO)Article 19(1)(g)Article 21Judicial ActivismHealthcare RegulationPharmaceutical PricingRight to HealthEconomic Extortion

More in Constitution & Law

With working strength of just 2, Sikkim HC unable to hear intra-court appeals

07 Nov 2026

Supreme Court issues contempt notice to office-bearers of KPCC for online post targeting CJI

07 Nov 2026

Schools must address bullying based on gender identity, sexual orientation: High Court

05 Nov 2026

Marital discord no ground for termination of pregnancy: SC